Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus RoyaltiesGlobeNewsWire • 12/21/20
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell DiseaseGlobeNewsWire • 12/07/20
Agios Pharmaceuticals (AGIO) Up 6.2% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/05/20
Agios Launches Anemia ID, a No-Cost Genetic Testing Program for Hereditary AnemiasGlobeNewsWire • 11/30/20
Agios to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020GlobeNewsWire • 11/25/20
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell DiseaseGlobeNewsWire • 11/12/20
Agios Pharmaceuticals' (AGIO) CEO Jackie Fouse on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/06/20
Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the Virtual 2020 ASH Annual MeetingGlobeNewsWire • 11/04/20
Agios to Host a Webinar on its Pyruvate Kinase-R (PKR) Activation Clinical Programs and Commercial Outlook on Thursday, November 19, 2020GlobeNewsWire • 10/29/20
Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 10/22/20
Agios to Webcast Conference Call of Third Quarter 2020 Financial Results on November 5, 2020GlobeNewsWire • 10/22/20
Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid LeukemiaGlobeNewsWire • 10/16/20
All You Need to Know About Agios Pharmaceuticals (AGIO) Rating Upgrade to BuyZacks Investment Research • 10/05/20
Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma PatientsGlobeNewsWire • 09/21/20
Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate AffairsGlobeNewsWire • 09/08/20